159 related articles for article (PubMed ID: 38200251)
1. Incidence and risk factors for febrile neutropenia of patients with diffuse large B-cell lymphoma receiving R-CHOP-21 in China.
Zheng W; Chen Z; Zhu S; Cheng L; Hu Y; Yang Y; Tan M; Ning H; Guan L
Support Care Cancer; 2023 Dec; 32(1):43. PubMed ID: 38200251
[TBL] [Abstract][Full Text] [Related]
2. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
Lugtenburg P; Silvestre AS; Rossi FG; Noens L; Krall W; Bendall K; Szabo Z; Jaeger U
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):297-305. PubMed ID: 23040435
[TBL] [Abstract][Full Text] [Related]
3. Predictive Parameters of Febrile Neutropenia and Clinical Significance of G-CSF Receptor Signaling Pathway in the Development of Neutropenia during R-CHOP Chemotherapy with Prophylactic Pegfilgrastim in Patients with Diffuse Large B-Cell Lymphoma.
Kim DY; Nam J; Chung JS; Jeon BE; Lee JH; Jo JC; Kim SW; Shin HJ
Cancer Res Treat; 2022 Oct; 54(4):1256-1267. PubMed ID: 34990523
[TBL] [Abstract][Full Text] [Related]
4. Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
Choi YW; Jeong SH; Ahn MS; Lee HW; Kang SY; Choi JH; Jin UR; Park JS
J Korean Med Sci; 2014 Nov; 29(11):1493-500. PubMed ID: 25408580
[TBL] [Abstract][Full Text] [Related]
5. Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma.
Pettengell R; Johnsen HE; Lugtenburg PJ; Silvestre AS; Dührsen U; Rossi FG; Schwenkglenks M; Bendall K; Szabo Z; Jaeger U
Support Care Cancer; 2012 Mar; 20(3):647-52. PubMed ID: 22101611
[TBL] [Abstract][Full Text] [Related]
6. G-CSF use in patients receiving first-line chemotherapy for non-Hodgkin's lymphoma (NHL) and granulocyte-colony stimulating factors (G-CSF) as observed in clinical practice in Italy.
Vitolo U; Angrili F; DeCosta L; Wetten S; Federico M
Med Oncol; 2016 Dec; 33(12):139. PubMed ID: 27822615
[TBL] [Abstract][Full Text] [Related]
7. Factors for the optimal selection of granulocyte colony-stimulating factor preparations and predictors for R-CHOP dose reductions/delays among patients with non-Hodgkin B-cell lymphoma (STOP FN in NHL 2 subanalysis).
Yokoyama M; Kusano Y; Inoue N; Nishimura N; Mishima Y; Nukada T; Hatake K; Terui Y
BMC Cancer; 2021 Apr; 21(1):358. PubMed ID: 33823836
[TBL] [Abstract][Full Text] [Related]
8. Incidence and risk factors of febrile neutropenia in patients with non-Hodgkin B-cell lymphoma receiving R-CHOP in a single center in Japan.
Yokoyama M; Kusano Y; Takahashi A; Inoue N; Ueda K; Nishimura N; Mishima Y; Terui Y; Nukada T; Nomura T; Hatake K
Support Care Cancer; 2017 Nov; 25(11):3313-3320. PubMed ID: 28551843
[TBL] [Abstract][Full Text] [Related]
9. Risks and consequences of travel burden on prophylactic granulocyte colony-stimulating factor administration and incidence of febrile neutropenia in an aged Medicare population.
Stephens JM; Bensink M; Bowers C; Hollenbeak CS
Curr Med Res Opin; 2019 Feb; 35(2):229-240. PubMed ID: 29661043
[TBL] [Abstract][Full Text] [Related]
10. Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP: the Intergroup experience (CALGB 9793; ECOG-SWOG 4494).
Morrison VA; Weller EA; Habermann TM; Li S; Fisher RI; Cheson BD; Peterson BA
Leuk Lymphoma; 2017 Aug; 58(8):1814-1822. PubMed ID: 27967294
[TBL] [Abstract][Full Text] [Related]
11. Incidence and risk factors for febrile neutropenia in Japanese patients with non-Hodgkin B cell lymphoma receiving R-CHOP: 2-year experience in a single center (STOP FN in NHL 2).
Yokoyama M; Kusano Y; Nishihara A; Inoue N; Nishimura N; Mishima Y; Terui Y; Nukada T; Nomura T; Hatake K
Support Care Cancer; 2020 Feb; 28(2):571-579. PubMed ID: 31093770
[TBL] [Abstract][Full Text] [Related]
12. [Use of granulocyte-colony stimulating factor(G-CSF)in patients with cancer at high risk of febrile neutropenia on the basis of high age and complications, recommendations for patients receiving radiotherapy, and adverse events because of G-CSF].
Hanada N; Tanaka S; Takahata T; Sato A
Gan To Kagaku Ryoho; 2014 Jun; 41(6):702-6. PubMed ID: 25129083
[TBL] [Abstract][Full Text] [Related]
13. Primary prophylactic granulocyte colony-stimulating factor according to ASCO guidelines has no preventive effect on febrile neutropenia in patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy.
Kawahira M; Yokota T; Hamauchi S; Kawai S; Yoshida Y; Onozawa Y; Tsushima T; Todaka A; Machida N; Yamazaki K; Fukutomi A; Yasui H
Int J Clin Oncol; 2018 Dec; 23(6):1189-1195. PubMed ID: 29948238
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of two pegfilgrastim biosimilars: Tripegfilgrastim and pegteograstim.
Kang KW; Lee BH; Jeon MJ; Yu ES; Kim DS; Lee SR; Sung HJ; Choi CW; Park Y; Kim BS
Cancer Med; 2020 Sep; 9(17):6102-6110. PubMed ID: 32633471
[TBL] [Abstract][Full Text] [Related]
15. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients.
Renner P; Milazzo S; Liu JP; Zwahlen M; Birkmann J; Horneber M
Cochrane Database Syst Rev; 2012 Oct; 10():CD007913. PubMed ID: 23076939
[TBL] [Abstract][Full Text] [Related]
16. The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: findings from clinical practice.
Salar A; Haioun C; Rossi FG; Duehrsen U; Pettengell R; Johnsen HE; Jaeger U; Verhoef G; Schwenkglenks M; Bacon P; Bendall K; Lugtenburg PJ
Leuk Res; 2012 May; 36(5):548-53. PubMed ID: 22385870
[TBL] [Abstract][Full Text] [Related]
17. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
Aapro MS; Bohlius J; Cameron DA; Dal Lago L; Donnelly JP; Kearney N; Lyman GH; Pettengell R; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
Eur J Cancer; 2011 Jan; 47(1):8-32. PubMed ID: 21095116
[TBL] [Abstract][Full Text] [Related]
18. Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia.
Aarts MJ; Peters FP; Mandigers CM; Dercksen MW; Stouthard JM; Nortier HJ; van Laarhoven HW; van Warmerdam LJ; van de Wouw AJ; Jacobs EM; Mattijssen V; van der Rijt CC; Smilde TJ; van der Velden AW; Temizkan M; Batman E; Muller EW; van Gastel SM; Borm GF; Tjan-Heijnen VC
J Clin Oncol; 2013 Dec; 31(34):4290-6. PubMed ID: 23630211
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for neutropenic fever in non-Hodgkin's lymphoma patients with primary granulocyte colony-stimulating factor prophylaxis.
Kim YR; Kim SJ; Park Y; Oh SY; Yun HJ; Mun YC; Kim JS;
Korean J Intern Med; 2021 Sep; 36(5):1181-1189. PubMed ID: 34265889
[TBL] [Abstract][Full Text] [Related]
20. Pegfilgrastim Prophylaxis Is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥ 75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study.
Jeong SH; Kim SJ; Yoon DH; Park Y; Kang HJ; Koh Y; Lee GW; Lee WS; Yang DH; Do YR; Kim MK; Yoo KH; Choi YS; Yun HJ; Yi JH; Jo JC; Eom HS; Kwak JY; Shin HJ; Park BB; Hyun SY; Yi SY; Kwon JH; Oh SY; Kim HJ; Sohn BS; Won JH; Kim SH; Lee HS; Suh C; Kim WS
Cancer Res Treat; 2022 Oct; 54(4):1268-1277. PubMed ID: 34990525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
